PUBLIC COMPANY
save$APLSApellis Pharmaceuticals, Inc.
$APLS41.030.00%Waltham, MA, USupdated 15d ago
community read0 votes
pipeline
2
marketed
2
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
- phase3Pegcetacoplan Long Term Safety and Efficacy Extension Study
- phase2Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
- phase3An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
- phase2A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
- phase3A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
- —A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- phase3Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Apr 17, 26giftSullivan Timothy Eugene · Chief Financial Officer11,096 sh
- Apr 17, 26giftSullivan Timothy Eugene · Chief Financial Officer11,096 sh
- Apr 6, 26otherO'Brien Stephanie Monaghan · director5,750 sh
- Mar 11, 26giftFrancois Cedric · Chief Executive Officer64,869 sh
- Mar 11, 26giftFrancois Cedric · Chief Executive Officer64,869 sh
- Feb 27, 26grantDolsten Mikael · director24,135 sh
🐶 Hiring Signal
News
- ‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a whileBiogen's business development team may have been busy in recent years, but CEO Christopher Viehbacher is easing off the acquisitions for a while.fiercebiotech · 16d ago
- Vertex to acquire Crinetics in $10B foray into endocrine disease drugsVertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.biopharma_dive · 1mo ago
- Biogen adds more immune drugs in $1B buyout of secretive startup RayTheraThe companies didn’t specify the drugs Biogen is acquiring in the deal, though patents RayThera secured provide important clues.biopharma_dive · 1mo ago
- Pfizer CFO to depart; GSK wins approval for UTI drugPlus news about Apellis Pharmaceuticals, Servier, TORL BioTherapeutics, Verastem, Corcept Therapeutics, Legend Biotech, COUR Pharmaceuticals, cAMPfield Therapeutics and LabGenius Therapeutics. 👋 P…endpoints · 1mo ago
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that